peter_wheatley_price

Takeda UK names new market access director

pharmafile | January 25, 2017 | Appointment | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Takeda 

Takeda UK has appointed Peter Wheatley Price to the role of market access director, where he will also sit on the senior leadership team. Price joins Takeda from a similar role at GSK, where he performed the role of director of global market access and pricing. He will be tasked with ensuring Takeda’s products enter the UK market, especially treatments for inflammatory bowel disease, diabetes and oncology, whilst also working upon reimbursement and pricing for Takeda’ portfolio.

Peter Wheatley Price stated upon his appointment: “I have been very fortunate in my career to work on a number of molecules that have made a significant, palpable difference to patients’ lives. I was attracted to Takeda because of its outstanding portfolio and culture of putting the patient at the centre, supported by strong values.”

The person to whom he will report, Adam Zaeske, commented on Price’s appointment: “Owing to our ambitions to continue to deliver improved outcomes both for patients and our customers, I am delighted that we have been able to attract such a strong talent as Peter to take on such an important role in our organisation. It is clear to me that he shares our vision for Takeda and has both the experience and passion to help us to grow the business.”

Advertisement

Related Content

Von Willebrand disease – increasing awareness and access to vital care

Pharmafile talks to Anthea Cherednichenko, Vice President Franchise Head Haematology and Transplant at Takeda about …

Combination treatments: Takeda’s Implementation Framework and the broader landscape

Pharmafile talks to Emma Roffe, Oncology Country Head (UK & Ireland) about the combination treatment …

Takeda presents positive results from trial of chronic kidney disease treatment

Takeda Pharmaceuticals has announced positive results from a proof-of-concept study of mezagitamab (TAK-079) to treat …

The Gateway to Local Adoption Series

Latest content